Therapeutic areas

From cardiovascular health to oncology, Viatris offers quality treatment options across more than 10 major therapeutic areas covering a wide variety of noncommunicable and infectious diseases. We also offer support services such as diagnostic clinics, educational seminars and digital tools to help patients better manage their health.

We offer a broad and diverse range of treatment options across all our therapeutic areas, with many categories containing several products in a range of dosage forms, formulations and delivery systems that allow physicians to tailor care for optimal treatment.

Cardiovascular

Infectious disease

Oncology

Immunology

CNS and anesthesia

Women's healthcare

Diabetes and metabolism

Gastroenterology

Respiratory and allergy

Dermatology

We are committed to meaningfully reducing the burden of both noncommunicable and infectious diseases by leveraging our scientific, medical, manufacturing and commercial expertise to develop holistic, integrated solutions for diagnosis, prevention and treatment of these conditions.

Easing the burden of noncommunicable diseases

According to the World Health Organization (WHO), noncommunicable diseases (NCDs), such as ischemic heart disease, stroke, diabetes, certain cancers and chronic obstructive pulmonary disease, were among the leading causes of death globally as of 2019.1 NCDs affect people of every age, gender and socioeconomic status in every corner of the world, and pose a heavy burden on individuals, families and communities. To overcome this global public health threat, patients worldwide need a partner they can trust – one that not only believes everyone deserves good health, but also has the portfolio, experience and expertise to make this belief a reality.

Collaborating to help people stay healthier

Viatris collaborates with many organizations to help prevent, diagnose and treat NCDs. Our deep experience in emerging and developed markets affords a tried-and-true method of achieving high impact across the patient experience, from awareness to adherence. In close collaboration with government, healthcare providers, technology partners and patients, we at Viatris will work to nurture healthcare systems that can adapt and respond to patients’ ever-changing needs. We continue to collaborate with medical associations, patient advocacy groups and academia to develop innovative, integrated solutions and programs to help strengthen both the delivery and quality of healthcare – ultimately, to reduce the burden of NCDs.

Select examples of our partnerships include:

  • The NCD Academy, a novel web-based platform developed in partnership with the American College of Cardiology (ACC), the World Heart Federation (WHF) and the NCD Alliance (NCDA), which provides healthcare professionals with educational resources to enhance their clinical skills and improve knowledge on overall NCD management. The program enables physicians and global health authorities to develop data driven NCD mitigation strategies that can ultimately help improve health outcomes.
  • The Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network to support their mission of improving the management of hypertension and organ protection. Through this partnership, we are actively contributing to progress toward achieving “zero” cardiovascular events in Asia.
  • Project change, a joint program between Viatris and the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) initiative of the European Commission. The partnership aims to identify clinical practice and systems-related gaps in Europe in relation to the prevention and management of NCDs, healthy aging, and support the necessary changes in clinical practice. Five grants have been provided to independent organizations to pursue projects with patient quality of life at their core.
  • The World Psychiatric Association (WPA) to deliver continuing education and foster capability development, working together to achieve better health for those with mental illness and those at risk. Our partnership supports important projects such as overcoming stigma and leading the conversation on improving mental well-being.

To learn more about Viatris in NCDs, read our report “Creating an Integrated Approach to Noncommunicable Diseases.”

1https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.

"The Convergence of NCDs and Infectious Disease"

“At Viatris, our scientific approach to solving the twin burdens of infectious disease and NCDs is through application of implementation science principles to address translation gaps and drive collaborations toward integrated care to address the interconnectedness of diseases.”
Shekhar Potkar, MD, MBA Head of Medical Affairs - Emerging Markets & NCD Excellence, Viatris

Read about the how HIV and NCD epidemics are converging.

Fighting infectious disease

We are also a global leader in treating infectious diseases such as HIV/AIDS, hepatitis and tuberculosis, and offer an extensive portfolio across these disease states. While many important strides have been made to treat these illnesses, there is still more to be done, especially in low- and lower-middle-income countries, where lack of access to therapeutics preventative treatment and diagnostics often result in patients not receiving proper care. High-income countries face infectious disease challenges as well, where HIV transmission continues 30 years into the epidemic. From manufacturing a pediatric-friendly antiretroviral(ARV) used to treat HIV-positive infants to providing HIV self-tests in some low- and middle-income countries, we are innovating to help patients.

100+

Our HIV products

Countries supplied by Viatris with ARV treatments in 2021, including countries facing the highest burdens of HIV and tuberculosis (TB).

Select Viatris infectious disease initiatives include:

  • Collaborating with Otsuka and TB Alliance to increase access to effective antimicrobials for multi-drug resistant (MDR) and extensively drug resistant (XDR) forms of tuberculosis in high-burden countries
  • Being first-to-market with a next-generation HIV treatment, and partnering with UNAIDS, the United States President’s Emergency Plan for AIDS Relief (PEPFAR), and others, to make it available at low cost to public sector purchasers in low- and middle-income countries around the world
  • Developing a child-friendly formulation of the WHO’s preferred pediatric HIV treatment, for which Viatris was named 5th on Fortune's 2021 Change The World List.
  • Launching the first pan-genotypic treatment regimen for hepatitis C approved by the WHO pre-qualification of medicines program
  • Expanding access to a more effective treatment for cryptococcal meningitis (CM), one of the leading causes of death in people with advanced HIV/AIDS, via partnerships and a clinical access program in South Africa.